iCo Therapeutics announced the formation of an oral Amphotericin B clinical advisory board with the appointment of Dr. John Perfect and Dr. David Denning. John R. Perfect, MD is James B Duke Professor of Medicine and is associated with Duke University, Professor of Molecular Genetics and Microbiology and Chief of Infectious Diseases. His general research focus for four decades has been on cryptococcosis: pathogenesis and management. He also investigates other fungal infections through translational and clinical trials. He interacts as a consultant for many pharmaceutical companies in the antifungal space. Along with his basic science research portfolio, he also attends to patients at the beside. He is President of the Mycoses Study Group (MSG) based in USA and President-elect of the international Society of Human and Animal Mycology (ISHAM). Dr. Denning is an infectious diseases clinician with expertise in fungal diseases. He serves as the Chief Executive of the Global Action Fund for Fungal infections (GAFFI) and Professor of Infectious Diseases and Global Health at the University of Manchester, UK. Dr. Denning manages the National Aspergillosis Centre, Manchester. He is the Executive Director of the Global Action Fund for Fungal Infections.